Literature DB >> 14712298

5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene.

C Fuerer1, R Iggo.   

Abstract

Clinical studies with oncolytic adenoviruses have shown that existing viruses are safe but lack efficacy. To selectively increase the toxicity of oncolytic adenoviruses targeting colon tumours, we have inserted the yeast cytosine deaminase gene (yCD) after the fibre gene in the major late transcript. yCD was expressed using either an internal ribosome entry site (IRES) or by alternative splicing of a new exon analogous to the Ad41 long fibre exon. The IRES-CD virus gave higher yCD expression on Western blots. Both approaches result in yCD expression restricted to the period after viral DNA replication. Viral burst size was reduced by less than approximately 10-fold by 5-fluorocytosine (5-FC), showing that expression of yCD as a late gene is compatible with virus replication. Cytopathic effect assays in colon cancer cell lines showed that both yCD viruses have approximately 10-fold increased toxicity in the presence of the prodrug 5-FC, which is converted to 5-fluorouracil (5-FU) by yCD. Toxicity was higher following addition of 5-FC immediately after infection. The largest gain in toxicity was seen in HT29 colon cancer cells, which are the least permissive colon cancer cells for the parental virus, indicating that the new 5-FC/yCD viruses may have broader applications for colon cancer therapy than their predecessors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14712298     DOI: 10.1038/sj.gt.3302148

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

Review 1.  Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.

Authors:  Sonia Tusell Wennier; Jia Liu; Grant McFadden
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

2.  A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.

Authors:  Tanja Hakkarainen; Akseli Hemminki; David T Curiel; Jarmo Wahlfors
Journal:  Int J Mol Med       Date:  2006-10       Impact factor: 4.101

3.  Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy.

Authors:  Christina Quirin; Stanimira Rohmer; Inés Fernández-Ulibarri; Michael Behr; Andrea Hesse; Sarah Engelhardt; Philippe Erbs; Alexander H Enk; Dirk M Nettelbeck
Journal:  Hum Gene Ther       Date:  2011-02-02       Impact factor: 5.695

Review 4.  The application of oncolytic viruses in cancer therapy.

Authors:  Yang Gao; Yan Wu; Tian Huan; Xiaoyan Wang; Jun Xu; Qinggang Xu; Feng Yu; Haifeng Shi
Journal:  Biotechnol Lett       Date:  2021-08-26       Impact factor: 2.461

Review 5.  Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.

Authors:  Phuong N Le; Jessica D McDermott; Antonio Jimeno
Journal:  Pharmacol Ther       Date:  2014-08-27       Impact factor: 12.310

Review 6.  Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.

Authors:  Dirk M Nettelbeck
Journal:  J Mol Med (Berl)       Date:  2007-12-19       Impact factor: 4.599

Review 7.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

Review 8.  Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.

Authors:  Martí Farrera-Sal; Cristina Fillat; Ramon Alemany
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

9.  Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral Fitness.

Authors:  Martí Farrera-Sal; Jana de Sostoa; Estela Nuñez-Manchón; Rafael Moreno; Cristina Fillat; Miriam Bazan-Peregrino; Ramon Alemany
Journal:  Int J Mol Sci       Date:  2020-07-21       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.